Anzeige
Meldung des Tages: Der Vorteil des Meeresbodens: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

AbbVie News

Aktie
WKN:  A1J84E ISIN:  US00287Y1091 US-Symbol:  ABBV Branche:  Pharmazeutika Land:  USA
178,50 €
+1,75 €
+0,99%
17:32:24 Uhr
Depot/Watchlist
Marktkapitalisierung *
345,80 Mrd. €
Streubesitz
24,69%
KGV
21,69
Dividende
5,85 EUR
Dividendenrendite
3,05%
Nachhaltigkeits-Score
54 %
Index-Zuordnung
S&P 500
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,37: MM05E1
Werbung

AbbVie News

23.02.26 - PR Newswire
AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States
AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States PR Newswire
21.02.26 wallstreetONLINE Redaktion
Community Rückblick: wO-User zur Newron Kapital­erhöhung: "Tja, wir wurden wohl mächtig verarscht"
Newron ist zurück an der Spitze der wallstreetONLINE-​Diskussionen. Grund: Bis zu 38 Mio. € Finanzierung für das Phase-​III-Programm Evenamide (Schizophrenie). Die Community ...
20.02.26 wallstreetONLINE Redaktion
Pharma-Dividenden-Wert: AbbVie greift auf dem Abnehm-Markt an: Wird das die nächste Milliarden-Chance?
GLP-1-Abnehmpräparate bringen neue Kunden in Beauty-​Praxen – und setzen AbbVies Faltenmittel Juvéderm unter Druck. Die Analysten von Berenberg sehen zugleich neue ...
20.02.26 - PR Newswire
U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic ...
19.02.26 - PR Newswire
AbbVie Declares Quarterly Dividend
AbbVie Declares Quarterly Dividend PR Newswire
17.02.26 - ARIVA.DE Redaktion
AbbVie: Immunologie-Marktführer mit wachsendem Onkologie-Potenzial – Chance trotz Humira-Druck?
AbbVie festigt seine dominierende Stellung in der Immunologie und baut parallel ein wachstumsstarkes Onkologie-​Portfolio auf. Trotz des anhaltenden Gegenwinds durch den ...
10.02.26 - PR Newswire
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market PR Newswire
04.02.26 - PR Newswire
AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
AbbVie Reports Full-Year and Fourth-​Quarter 2025 Financial Results PR Newswire
03.02.26 - PR Newswire
Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program
Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program PR Newswire
03.02.26 - PR Newswire
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo PR Newswire
30.01.26 - PR Newswire
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
$170B Patent Cliff Ignites Biotech Deal Wave: Late-​Stage Platforms Command Premium PR Newswire
29.01.26 - PR Newswire
AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships
AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships PR Newswire
28.01.26 - PR Newswire
Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine
Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine ...
16.01.26 - PR Newswire
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell ...
12.01.26 - PR Newswire
AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans PR Newswire
12.01.26 - PR Newswire
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors PR Newswire
12.01.26 - PR Newswire
AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States PR Newswire
12.01.26 - PR Newswire
West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie
West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie PR Newswire
07.01.26 - PR Newswire
AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
AbbVie to Host Full-Year and Fourth-​Quarter 2025 Earnings Conference Call PR Newswire
06.01.26 wallstreetONLINE Redaktion
Wachstum, Pipeline, Cash: Diese Pharma-Story überzeugt
Immunologie liefert starkes Wachstum, der Cashflow sprudelt und die Pipeline bringt neue Fantasie. Trotz kräftiger Kurs­gewinne sehen Analysten weiteres Potenzial für diese ...

Newssuche

Videos

newspaper
16.04.26 +3,58%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »